- Home
- MYGN vs MYI Comparison
MYGN vs MYI Comparison
Compare MYGN & MYI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MYGN
- MYI
- Stock Information
- Founded
- MYGN 1991
- MYI 1992
- Country
- MYGN United States
- MYI United States
- Employees
- MYGN N/A
- MYI N/A
- Industry
- MYGN Biotechnology: In Vitro & In Vivo Diagnostic Substances
- MYI Investment Bankers/Brokers/Service
- Sector
- MYGN Health Care
- MYI Finance
- Exchange
- MYGN Nasdaq
- MYI Nasdaq
- Market Cap
- MYGN 744.7M
- MYI 697.2M
- IPO Year
- MYGN 1995
- MYI N/A
- Fundamental
- Price
- MYGN $5.34
- MYI $10.49
- Analyst Decision
- MYGN Hold
- MYI
- Analyst Count
- MYGN 15
- MYI 0
- Target Price
- MYGN $15.14
- MYI N/A
- AVG Volume (30 Days)
- MYGN 1.3M
- MYI 256.7K
- Earning Date
- MYGN 08-05-2025
- MYI 01-01-0001
- Dividend Yield
- MYGN N/A
- MYI 4.81%
- EPS Growth
- MYGN N/A
- MYI N/A
- EPS
- MYGN N/A
- MYI N/A
- Revenue
- MYGN $831,300,000.00
- MYI N/A
- Revenue This Year
- MYGN N/A
- MYI N/A
- Revenue Next Year
- MYGN $6.68
- MYI N/A
- P/E Ratio
- MYGN N/A
- MYI N/A
- Revenue Growth
- MYGN 7.38
- MYI N/A
- 52 Week Low
- MYGN $3.81
- MYI $9.32
- 52 Week High
- MYGN $29.30
- MYI $11.70
- Technical
- Relative Strength Index (RSI)
- MYGN 50.85
- MYI 49.45
- Support Level
- MYGN $4.90
- MYI $10.37
- Resistance Level
- MYGN $5.83
- MYI $10.63
- Average True Range (ATR)
- MYGN 0.28
- MYI 0.07
- MACD
- MYGN 0.04
- MYI 0.01
- Stochastic Oscillator
- MYGN 54.21
- MYI 42.86
About MYGN Myriad Genetics Inc.
Myriad Genetics Inc is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel capable of identifying the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm also offers pharma and biotech companies biomarker discovery and companion diagnostic services.
About MYI Blackrock MuniYield Quality Fund III Inc
BLACKROCK MUNIYIELD QUALITY FUND III, INC. is a investment management company. Its investment objective is to provide shareholders with a high level of current income exempt from U.S. federal income taxes as is consistent with its investment policies and prudent investment management. The company invests in various sectors such as Transportation; Utilities; Health; Education; Tobacco and others.